Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study)
Authors
Keywords
-
Journal
ANNALS OF THE RHEUMATIC DISEASES
Volume 73, Issue 1, Pages 75-85
Publisher
BMJ
Online
2013-08-03
DOI
10.1136/annrheumdis-2013-203440
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-Dose Prednisone Inclusion in a Methotrexate-Based, Tight Control Strategy for Early Rheumatoid Arthritis
- (2013) Marije F. Bakker ANNALS OF INTERNAL MEDICINE
- Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial
- (2013) Kim Hørslev-Petersen et al. ANNALS OF THE RHEUMATIC DISEASES
- Association Between the Initiation of Anti–Tumor Necrosis Factor Therapy and the Risk of Herpes Zoster
- (2013) Kevin L. Winthrop et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)
- (2012) Marjatta Leirisalo-Repo et al. ANNALS OF THE RHEUMATIC DISEASES
- Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial
- (2012) P H de Jong et al. ANNALS OF THE RHEUMATIC DISEASES
- Can flare be predicted in DMARD treated RA patients in remission, and is it important? A cohort study
- (2012) Benazir Saleem et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA study
- (2012) Arthur Kavanaugh et al. ANNALS OF THE RHEUMATIC DISEASES
- In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial
- (2011) Hamed Rezaei et al. ANNALS OF THE RHEUMATIC DISEASES
- American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials
- (2011) David T. Felson et al. ARTHRITIS AND RHEUMATISM
- Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry
- (2011) María José Pérez-Sola et al. MEDICINA CLINICA
- Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
- (2010) R. Knevel et al. ANNALS OF THE RHEUMATIC DISEASES
- Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
- (2010) M. Schoels et al. ANNALS OF THE RHEUMATIC DISEASES
- EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Treating rheumatoid arthritis to target: recommendations of an international task force
- (2010) J. S. Smolen et al. ANNALS OF THE RHEUMATIC DISEASES
- Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
- (2010) J. L. Nam et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
- (2009) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
- (2009) RF van Vollenhoven et al. LANCET
- An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis
- (2008) A. K. Brown et al. ARTHRITIS AND RHEUMATISM
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started